Senior Manager Business Development Early Access

Job description

Inceptua is a global pharmaceutical services company with market-leading capabilities across multiple business areas. We have over 25 years of experience serving life science companies of various sizes and global operations with offices across Europe, North America, and Asia.

Inceptua is a world leader in the Early Access (also known as Named Patient, Compassionate Use, Expanded Access, Managed Access) space. We offer strategic advice, design, facilitation, and implementation of global early access programs on behalf of pharmaceutical and biotech companies, and distributes unlicensed medicines worldwide.

Our success is based on the motivation, dedication and performance of our people. We strive to go the extra mile and achieve excellence in all our services. 

We are hiring for the position of Senior Manager, Business Development, Early Access to be based in the USA for an immediate start.

You will report to the EVP, Early Access and will support the Early Access business unit through prospecting and developing leads for new business opportunities, supporting with background research relating to business development and client requirements, design and delivery of consultancy projects, and preparing proposals in relation to RFPs for Early Access Programs.

Responsibilities include, but are not limited to:

  • Identify, research, and qualify new business opportunities through market and pipeline analysis.
  • Conduct BD outreach to potential partners and represent the company at key conferences and industry events.
  • Cultivate strategic relationships with biopharmaceutical clients and regional prospects to build and expand a long-term business pipeline and achieve agreed targets.
  • Uncover and track potential Early Access new business opportunities and secure awards with new and existing clients.
  • Develop and submit proposals that offer bespoke and valued services and solutions based on a thorough understanding of prospective client needs
  • Support the continuous improvement of BD processes, reporting, and tools to enhance efficiency and transparency across the function.
  • Facilitate and participate in initial engagement with potential client companies, and in bid defense meetings.
  • Contribute to the design and delivery of consultancy projects, providing analytical input, commercial insight, and strategic recommendations to clients and internal stakeholders.
  • Drive the completion of contracting with clients in a timely manner.
  • Achieve revenue, gross profit and growth goals by securing new business opportunities with new and existing client companies.
  • Collaborate with BD staff and other internal stakeholders to execute a marketing plan for EA activities, including conference attendance and management, materials, branding and though leadership
  • Maintain training and compliance with Inceptua SOPs and standards and seek new opportunities to develop in role
  • Track ongoing industry development pipelines and portfolios to support continued business development activities
  • Work collaboratively within Early Access and other Inceptua business groups to foster productive working relationships and focus on achieving client satisfaction and timely delivery
  • Maintain and enhance the company’s CRM system, ensuring accurate and timely tracking of leads, opportunities, and partner interactions

Your profile:

  • Experience in business development, commercial strategy, or consultancy within the pharmaceutical or biotech industry
  • Strong analytical and research capabilities, with the ability to interpret medical, scientific and commercial data to develop highly relevant and tailored solutions for Pharma clients
  • Excellent written and verbal communication skills; confident in developing proposals and engaging external partners
  • Working knowledge of CRM platforms and data analysis tools (e.g., Salesforce, NetSuite, Dynamics 365, Excel, Power BI, or similar).
  • Experience working in Early Access / unlicensed medicines is strongly preferred
  • Educated to at least degree level in a science or business-related discipline
  • Collaborative, organised, and proactive, with a balance of strategic perspective and attention to detail
  • Comfortable managing multiple workstreams across BD, consultancy, commercial operations and strategy
  • Willingness to travel for conferences and partner meetings as required

This position is full-time.

Our company is home to employees from various backgrounds that speak a range of languages. With teams across different locations and cultures, we value diversity and believe that inclusive collaboration makes us stronger.

Apply now!

View all open positions
BIO

CEO and Board Member

Stefan Fraenkel

Stefan Fraenkel is the CEO of the Inceptua Group and is also on the Inceptua Board. He has extensive experience in the pharmaceutical industry. Before joining Inceptua, he held senior management positions at Sobi (Swedish Orphan Biovitrum), Sweden’s largest publicly listed specialty pharmaceutical company, leading Marketing & Sales and serving as Head of Corporate Development and Strategy.

Previously, Stefan worked at Pfizer and Wyeth in international commercial leadership roles across Europe and the USA, gaining deep insights into global pharmaceutical markets and strategies. Stefan has also spent part of his career in management consulting. Stefan holds a PhD in International Economics, an MBA, and a BSc in Engineering.

BIO

Member of the Board

Chris Hasslinger

Chris Hasslinger is a Partner of Vesey Street Capital Partners and serves as a member of the Firm’s Investment Committee. He joined VSCP in 2023 and is responsible for sourcing and evaluating new investment opportunities and general portfolio company management. Mr. Hasslinger has nearly three decades of experience in healthcare and technology strategy and deal-making within the industry as well as in investment banking and private equity. He has extensive M&A experience, having closed over $20 billion in transaction value, and has established and structured a number of large commercial partnerships.

BIO

Executive Vice Chairman

Alan Raffensperger

Alan Raffensperger has a robust leadership background in the pharmaceutical industry, having served as CEO of Inceptua and COO of Sobi (Swedish Orphan Biovitrum), along with significant international executive roles at Amgen, Roche, and Pharmacia.

He has also been CEO for venture capital-owned medical device companies, showcasing his versatility in healthcare leadership. Alan’s early career as an advanced life support paramedic provided a strong foundation in emergency healthcare.

He holds an MBA and a BA in Emergency Health Care Management.

BIO

Member of the Board

Blake Goodner

Blake Goodner is a founder member of the investment firm Bridger Capital. He previously worked as a healthcare analyst at Tiger Management and a healthcare investment banker at Morgan Stanley. He currently serves as an advisor and board member for a range of healthcare companies. Mr. Goodner has been a member of the Trinity College Board of Visitors and the Duke Annual Fund Executive Committee. He is a current advisory board member with The Duke Margolis-Center for Health Policy.

BIO

Member of the Board

Adam Feinstein

Adam Feinstein is the Managing Partner of Vesey Street Capital Partners. Mr. Feinstein has 30 years of investment experience exclusively in the healthcare services sector. Prior to founding Vesey Street Capital Partners in 2014, he was a Managing Director on Wall Street and a healthcare industry executive. He held the position of Senior Vice President of Corporate Development, Strategic Investments, and Office of the Chief Executive Officer at LabCorp. Before his tenure at LabCorp, he spent 14 years as the Managing Director in Equity Research at Lehman Brothers/Barclays Capital. Mr. Feinstein is the Chairman of VSCP’s investment committee. He is also actively involved in working with portfolio company executives and sourcing new investment opportunities. At the same time, he oversees all of the firm’s investment activities and employees.

BIO

Member of the Board

Larry Marsh

Larry is a General Partner of Vesey Street Capital Partners and serves as a member of the Firm’s Investment Committee. He joined VSCP in 2016, and currently sits on the Board of QualityMetric, Safecor Health, and HRGi. He is responsible for portfolio company management and for evaluating new investment opportunities. Prior to VSCP, Larry was EVP, New Market Development & Chief Strategy Officer at Fortune 10 AmerisourceBergen. Prior to that, Larry was the #1 ranked Healthcare Technology & Distribution analyst on Wall Street for over a decade, at Barclays, Lehman Brothers, Salomon Smith Barney, and Wheat First Butcher & Singer. Larry worked with Adam, Bryan, Dan, and Joe at Barclays and Lehman. Larry received a B.S. in Economics & Management as well as an M.B.A. from the University of Richmond, and an M.P.H. from Columbia University.

BIO

Member of the Board

Heyward Donigan

Heyward Donigan is a seasoned healthcare CEO, Board Member, and Private Equity Advisor with broad industry experience and a track record of profitable growth. From 2019 to 2023, Ms. Donigan served as Rite Aid’s president and chief executive officer, making her one of the few women CEOs of a Fortune 500 company. While at Rite Aid, Ms. Donigan led the company to through a major brand, merchandise and technology transformation, debt reduction/refinancing, while also leading the company through a pandemic. Ms.Donigan is currently a strategic advisor to Vesey Street Capital Partners, Arima Health, and a board member of OnMed.

BIO

Executive Chairman

Doug Cook

Doug Cook is the Executive Chairman at Inceptua. Mr. Cook began his career driving the early success of Livingston Healthcare, leading to the purchase by UPS to become what is today UPS’s Global Healthcare business. After Livingston Healthcare, Mr. Cook moved to AmerisourceBergen (now called Cencora/COR) in 1998 and had an impressive career overseeing most of Cencora’s high growth, manufacturer-facing business. Mr. Cook ultimately served as the Executive Vice President, President Commercialization and Animal Health for COR.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE